

**REGISTRATION OF “DOCUMENT E” AND CLEARANCE OF ADMISSION PROSPECTUS  
RELATED TO THE PROPOSED CROSS-BORDER MERGER  
OF TOPOTARGET INTO BIOALLIANCE PHARMA**

**Paris, May 19, 2014** - BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announces today that on 26 May 2014, the *Autorité des Marchés Financiers* has registered the « *Document E* » (n° E.14-034) and granted clearance on the “*Prospectus d’admission*” (n° 14-232) related to the proposed cross-border merger of Topotarget A/S into BioAlliance Pharma SA.

The “*Document E*” and the “*Prospectus d’admission*” are available, free of charge upon request, at the registered office of BioAlliance Pharma and on its website, in French version and in English version -for information purposes only- ([www.bioalliancepharma.com](http://www.bioalliancepharma.com)), as well as on the website of the *Autorité des Marchés Financiers* ([www.amf-france.org](http://www.amf-france.org)).

**About BioAlliance Pharma**

Dedicated to cancer treatments with a focus on resistance targeting and orphan products, BioAlliance Pharma conceives and develops innovative products for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced Orphan Oncology products portfolio:

- Livatag<sup>®</sup> (Doxorubicin Transdrug<sup>™</sup>) (primary liver cancer): Phase III on going
- Validive<sup>®</sup> (Clonidine Lauriad<sup>®</sup>) (mucositis): Phase II on going
- AMEP<sup>®</sup>/synfoldin (invasive melanoma): Preclinical phase

For more information, visit the BioAlliance Pharma web site at [www.bioalliancepharma.com](http://www.bioalliancepharma.com).

**BioAlliance Pharma SA**

Judith Greciet, CEO  
[judith.greciet@bioalliancepharma.com](mailto:judith.greciet@bioalliancepharma.com)  
Nicolas Fellmann, CFO  
[nicolas.fellmann@bioalliancepharma.com](mailto:nicolas.fellmann@bioalliancepharma.com)  
Tel.: +33 1 45 58 76 00

**ALIZE RP**

Caroline Carmagnol  
+33 6 64 18 99 59  
[bap@alizerp.com](mailto:bap@alizerp.com)

**Important information**

This press release and the information contained in it do not constitute an offer to buy, sell or subscribe for any shares in Topotarget and/or BioAlliance Pharma in any country. The distribution, publication or release of this press release may be prohibited or restricted by the laws or regulations applicable in certain countries. Persons who are physically present in those countries and in countries where the press release is distributed, published, or released must comply with local restrictions.

This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States of America (the "United States") or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the "Securities Act") or another exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act. The merging companies are European companies. Information distributed in connection with the proposed merger and the related shareholder vote is subject to European disclosure requirements that are different from those of the United States. Financial statements and information may be prepared according to accounting standards which may not be comparable to those used generally by companies in the United States. It may be difficult for you to enforce your rights and any claim you may have arising under the U.S. federal securities laws in respect of the merger, since the companies have their registered offices outside the United States. You may not be able to sue the companies or their officers or directors in a European court for violations of the U.S. securities laws. It may also be difficult to compel the companies and their affiliates to subject themselves to a U.S. court's judgment.